Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis.

Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Res Rev. 2019 Nov 11;:100980 Authors: Livshits G, Kalinkovich A Abstract Sarcopenia, obesity and their coexistence, obese sarcopenia (OBSP) as well as atherosclerosis-related cardio-vascular diseases (ACVDs), including chronic heart failure (CHF), are among the greatest public health concerns in the ageing population. A clear age-dependent increased prevalence of sarcopenia and OBSP has been registered in CHF patients, suggesting mechanistic relationships. Development of OBSP could be mediated by a crosstalk between the visceral and subcutaneous adipose tissue (AT) and the skeletal muscle under conditions of low-grade local and systemic inflammation, inflammaging. The present review summarizes the emerging data supporting the idea that inflammaging may serve as a mutual mechanism governing the development of sarcopenia, OBSP and ACVDs. In support of this hypothesis, various immune cells release pro-inflammatory mediators in the skeletal muscle and myocardium. Subsequently, the endothelial structure is disrupted, and cellular processes, such as mitochondrial activity, mitophagy, and autophagy are impaired. Inflamed myocytes lose their contractile properties, which is characteristic of sarcopenia and CHF. Inflammation may increase the risk of ACVD events in a hyperlipidemia- independent manner. Significant reduction of ACVD event...
Source: Ageing Research Reviews - Category: Genetics & Stem Cells Authors: Tags: Ageing Res Rev Source Type: research

Related Links:

Conclusion: Our results suggest a different biochemical composition of S. polymorpha venom, based on the different effects of four venom fractions on the cells tested, according to statistical evidence. Fractions F6 and F7 caused the most important alterations.
Source: Journal of Venomous Animals and Toxins including Tropical Diseases - Category: Tropical Medicine Source Type: research
Publication date: Available online 29 May 2020Source: Physiology &BehaviorAuthor(s): Steven K. Malin, Emily M. Heiston, Nicole M. Gilbertson, Natalie Z.M. Eichner
Source: Physiology and Behavior - Category: Physiology Source Type: research
Publication date: Available online 29 May 2020Source: Redox BiologyAuthor(s): Shuai Li, Teng Wu, Yun-Xin Lu, Jin-Xiang Wang, Feng-Hai Yu, Mei-Zhu Yang, Yi-Jia Huang, Zhi-Jing Li, Sen-Lan Wang, Ling Huang, Lei Lu, Tian Tian
Source: Redox Biology - Category: Biology Source Type: research
Authors: Barp A, Gerardi F, Lizio A, Sansone VA, Lunetta C Abstract INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease involving both upper and lower motor neurons and resulting in increasing disability and death 3-5 years after onset of symptoms. Over 40 large clinical trials for ALS have been negative, except for Riluzole that offers a modest survival benefit, and Edaravone that modestly reduces disease progression in patients with specific characteristics. Thus, the discovery of efficient disease modifying therapy is an urgent need. AREAS COVERED: Althou...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research
We describe a new case of Leigh syndrome caused by a novel pathogenic variant of the C12orf65 gene resulting in the lack of the Gly-Gly-Gln (GGQ) domain in the predicted protein, and review clinical and molecular data from previously reported patients. Our study supports that the phenotype caused by C12orf65 gene variants is heterogeneous and varies from spastic paraparesis to Leigh syndrome. Loss-of-function variants are more likely to cause the disease, and variants affecting the GGQ domain tend to be associated with more severe phenotypes, reinforcing a possible genotype-phenotype correlation.
Source: Genetics and Molecular Biology - Category: Genetics & Stem Cells Source Type: research
Authors: Becattini C, Cimini LA Abstract INTRODUCTION: Anticoagulant treatment reduces recurrent venous thromboembolism (VTE) by about 90% after index pulmonary embolism. Whether anticoagulant treatment also reduces mortality in these patients remains to be defined. The main counterbalance for life long anticoagulation is the risk for anticoagulants-associated bleeding. AREAS COVERED: Literature search was performed in PubMed and Embase. We aimed to review the risk for recurrent VTE over time after discontinuation of anticoagulants and the risks for bleeding and for fatal bleeding over time during anticoagulant...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Conditions:   Healthy;   Obese;   Glucose Intolerance Intervention:   Procedure: Personalized cooling protocol Sponsor:   Leiden University Medical Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Hypertension;   Cardiovascular Risk Factor Intervention:   Behavioral: SMS group Sponsor:   Lund University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Myeloma;   Heart Failure;   Hypertension Intervention:   Sponsor:   European Georges Pompidou Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Bariatric Surgery Candidate;   Patient Underwent Bariatric Surgery Intervention:   Other: Telemedicine to remote outpatient visit in bariatric patient Sponsor:   University of Campania  " Luigi  Vanvitelli " Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cardiology | Cardiomyopathy | Eating Disorders & Weight Management | Genetics | Heart | Heart Failure | Hypertension | International Medicine & Public Health | Metabolic Syndrome | Mitochondrial Disease | Obesity | Thrombosis | Trimethylamine